Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.020 -0.010 (-0.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Why Editas Medicine Stock Is Soaring Today ↗
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
News headline image
Expert Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗
 
Via Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
Via Investor Brand Network
News headline image
Analyst Expectations for Editas Medicine's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
Is Editas Medicine Stock a Buy Now? ↗
The fortunes of this once-promising biotech company have changed in the past year. 
Via The Motley Fool
News headline image
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday ↗
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market... 
Via Benzinga
News headline image
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
What 6 Analyst Ratings Have To Say About Editas Medicine ↗
 
Via Benzinga
News headline image
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
News headline image
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
1 Gene Editing Stock to Buy Now, and 1 to Sell ↗
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
News headline image
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street ↗
Is the Street's optimism justified here? 
Via The Motley Fool
News headline image
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks ↗
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
News headline image
What Is CRISPR And Why Should Your Portfolio Care? ↗
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
News headline image
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock? ↗
It's not about to start making money anytime soon. 
Via The Motley Fool
News headline image
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
News headline image
2 Short-Squeeze Candidates That Could Go Parabolic ↗
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
News headline image
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Editas Medicine Announces Pricing of Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.